News Results

There are 797,969 News Results

Aug 30, 2024
KICK OFF FALL WITH TOP HOME APPLIANCE AND ENTERTAINMENT DEALS DURING LG'S LABOR DAY SAVINGS EVENT
Experience Huge Savings on LG Kitchen, Laundry, and Cleaning Appliances, TVs, Soundbars, Monitors, Laptops, and More
Aug 30, 2024
New pooled analysis published in The Lancet demonstrated reduced risk of combined CV death or worsening heart failure with semaglutide
-- Analysis conducted among 3,743 patients with history of heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction (HFpEF) from four clinical trials(1 ) --...
Sep 6, 2024
Dodge Enters Nitrocross Series, Dreyer & Reinbold Racing Team to Compete in 1,000-plus-horsepower Dodge Hornet R/T FC1-X Rally Cars
AUBURN HILLS, Mich., Sept. 6, 2024 /PRNewswire/ -- -- Dodge is entering the 2024-2025 Nitrocross Series with new Dodge Hornet R/T FC1-X electric-powered cars competing in the Group E class...
Sep 16, 2024
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (mPFS) of...
Sep 18, 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
FDA approval of a second strength for HERCESSI paves the way for Accord BioPharma to prepare to commercially launch its first biosimilar; several others are in active development
Sep 20, 2024
Astellas Receives Approval from the European Commission for VYLOY(TM) (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
-
Sep 24, 2024
Japan's Ministry of Health, Labour and Welfare Approves PADCEV(TM) (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing chemotherapy, the current standard of...
Sep 30, 2024
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
The new full visual range IOL*(1) delivers exceptional distance vision(2) and 14% smaller readable print size vs PanOptix(3 **).
Sep 30, 2024
Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related Heart Failure
- Results from the placebo-controlled study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) were presented in a Late Breaking Clinical Trial Plenary Session at the HFSA...
Oct 3, 2024
Cboe Global Markets Reports Trading Volume for September 2024
CHICAGO, Oct. 3, 2024 /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), the world's leading derivatives and securities exchange network, today reported September 2024 trading volume statistics across its global...
79797

Pages

1

Stories of the day

Oct 9, 2025
Viasat Awarded Contract by U.S. Space Force for Protected Tactical SATCOM-...
Oct 9, 2025
Damen Naval signs contract with Terma A/S for Decoy Launching System on...
Oct 10, 2025
INVISIO signs framework agreement worth up to SEK 365 million with Netherlands...
Oct 10, 2025
Rheinmetall to supply Leopard 1-based Skyranger 35 to Ukraine – contract value...